6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
27 citations
,
October 2001 in “Journal of Medicinal Chemistry” Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
5 citations
,
September 2022 in “Antioxidants” A substance from Caulerpa racemosa seaweed may protect against skin damage caused by air pollution by reducing oxidative stress and cell death.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
29 citations
,
June 2015 in “Kidney International” Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
1 citations
,
September 2021 in “Cureus” The rs1128977 gene variant may affect cholesterol and body measurements.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
1 citations
,
September 2004 in “Experimental Dermatology” MC-1R is present in skin cells and may help reduce inflammation.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
4 citations
,
April 2009 in “Journal of Pain” Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
Finding functions for unknown GPCRs is hard but key for making new drugs.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
7 citations
,
October 2015 in “Experimental dermatology” Blocking the mineralocorticoid receptor can help treat skin thinning caused by steroids.